Effect of Iodine treatment in patiënts with COVID-19 disease.
Phase 2
Recruiting
- Conditions
- lunginfection caused by viral infection10024970Viral infection pneumonia10047438
- Registration Number
- NL-OMON49526
- Lead Sponsor
- Maxima Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 224
Inclusion Criteria
Hospitalization and positive test for SARS-CoV-2 infection
Exclusion Criteria
Thyroid disease or treatment like goiter, thyroidectomie, radioactive iodine,
medication related to thyroid dysfunction or the use of Amiodaron
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Clinically relevant deterioration defined as:<br /><br>1. transfer from regular ward to IC department<br /><br>2. death in regular ward depatment<br /><br>3. death in IC department</p><br>
- Secondary Outcome Measures
Name Time Method <p>Total number of days in hospital and total number of deaths.</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie iodine's antiviral activity against SARS-CoV-2 in NL-OMON49526?
How does iodine treatment compare to remdesivir in reducing viral load for viral pneumonia patients?
Which biomarkers correlate with clinical response to iodine therapy in NL-OMON49526 phase II trial?
What adverse events are associated with high-dose iodine administration in respiratory viral infections?
Are there synergistic effects of iodine with corticosteroids in managing cytokine storm in NL-OMON49526?